非经典肿瘤多药耐药逆转剂的研究进展  

Research progress on atypical tumor multidrug resistance reversal agents

作　　者：张海燕[1] 庄俊雪 

机构地区：[1]天津市宝坻区人民医院,天津301800

出　　处：《现代药物与临床》2015年第6期747-752,共6页Drugs & Clinic

摘　　要：化疗是肿瘤综合治疗的主要手段之一,多药耐药性的产生是肿瘤化疗中存在的主要问题。开发多药耐药逆转剂逆转肿瘤细胞对现有化疗药物的耐药性将是一种有效的治疗方法。目前已有多种多药耐药逆转剂处于基础和临床试验阶段。主要从谷胱甘肽S转移酶、蛋白激酶C、凋亡通路受阻、拓扑异构酶和DNA修复能力增强等方面介绍非经典的多药耐药逆转剂。Chemotherapy plays an essential role in the combined therapy of tumor, while the emergence of multidrug resistance in tumor cells can always lead the therapy to failure. The development of multidrug resistance reversal agents is a promising approach to overcome the resistance of current chemotherapeutic agents. Presently, various kinds of reversal agents have already been in basic and clinical study. The research progress of atypical multidrug resistance reversal agents are summarized from glutathioneS-transferases, protein kinase C, block of apoptotic pathways, topoisomerase, and enhancement of DNA repair in this brief review.

关 键 词：多药耐药逆转剂 谷胱甘肽S转移酶 蛋白激酶C 拓扑异构酶Ⅱ DNA修复 

分 类 号：R979.1[医药卫生—药品]